OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
10
Results
Show all
Save search
Copy query
Show results for
Unknown
(10)
Publication Date
Release Date
2022
(2)
2021
(2)
2011
(2)
2023
(1)
2020
(1)
2018
(1)
2013
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Not available
S-EPMC5858523
|
biostudies-literature
Cite
The National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383
|
biostudies-literature
Cite
Proteogenomic Characterization of Endometrial Carcinoma.
Not available
S-EPMC7233456
|
biostudies-literature
Cite
Results of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922
|
biostudies-literature
Cite
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Not available
S-EPMC4356534
|
biostudies-literature
Cite
Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries.
Not available
S-EPMC10364528
|
biostudies-literature
Cite
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808
|
biostudies-literature
Cite
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Not available
S-EPMC8206995
|
biostudies-literature
Cite
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Not available
S-EPMC8652887
|
biostudies-literature
Cite
Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries.
Not available
S-EPMC9621702
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets